相关实验视频

Updated: Jul 17, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

在转移性前列腺癌中,IGF-1轴随着ADT和多塞变化而变化

Praful Ravi¹, Victoria Wang², Raina N Fichorova³

¹Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Endocrine-related cancer

|September 6, 2023

概括

在接受抗雄激素剥夺疗法 (ADT) 治疗的转移性前列腺癌男性中,更高的胰岛素样生长因子-1 (IGF-1) 与IGF结合蛋白1 (IGF-BP1) 比率与改善的整体存活率 (OS) 相相关. 这个比率可以作为治疗结果的预测生物标志物.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

抗雄激素剥夺疗法 (ADT) 是晚期前列腺癌 (PCa) 的主要治疗方法.
增长激素-胰岛素样生长因子 (GH-IGF-1) 轴与前列腺癌的发展有关.
GH-IGF-1轴在转移性PCa治疗反应中的作用尚未完全理解.

研究的目的:

调查胰岛素样生长因子-1 (IGF-1) 和其结合蛋白与转移性前列腺癌 (PCa) 患者接受ADT治疗的治疗结果之间的关联.
评估IGF-1轴作为预测整体存活率 (OS) 和抵御割性前列腺癌 (CRPC) 的时间的生物标志物的潜力.

主要方法:

在3期CHAARTED试验 (ADT +/- docetaxel) 中,从560名患者的血清样本中,在基线,6个月和进展时分析了IGF-1和IGF结合蛋白 (IGF-BP1,IGF-BP3,IGF-BP4).
统计分析评估了IGF-1轴蛋白和关键结果之间的关系:时间到CRPC和OS.

主要成果:

在ADT+多塞塔克塞尔组中,在6个月后观察到IGF-BP1,IGF-BP3和IGF-BP4的显著增加.
较高的IGF-1:IGF-BP1比率在基线和6个月与ADT和ADT + 多塞塔塞尔组的改善OS显著相关.
使用先前数据的元分析证实,较高的基线IGF-1:IGF-BP1比率预测了改善的OS.

结论:

IGF-1:IGF-BP1比率显示,作为转移性前列腺癌患者接受ADT的整体生存预测生物标志物具有前景.
对IGF-1轴的进一步研究是有必要的,以探索其治疗潜力和预测治疗反应中的作用.

关键词:

在IGF-1的基础上,IGF-1 在 IGF-BP1 中,雄激素剥夺疗法是一种治疗方法.化疗化疗是一种化学疗法.代谢代谢代谢代谢

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...